

SCIENCE'S COMPASS

ty is weak; published estimates of within-subject variability (15–17) indicate that CRP measurement could differ by 71 to 84% from an earlier reading. (iii) The likelihood of beneficial intervention is unknown. We don't know how to intervene (we don't understand the mechanisms underlying the observed associations), and we don't know if intervention alters outcomes. Taken together, these considerations argue in favor of caution before plunging ahead.

IRVING KUSHNER

MetroHealth Campus, Case Western Reserve University, 2500 MetroHealth Drive, Cleveland, OH 44109, USA. E-mail: ikushner@metrohealth.org


References

1. C. Gabay, I. Kushner, *N. Engl. J. Med.* **340**, 448 (1999).
2. I. Kushner, *Cleveland Clinic J. Med.* **68**, 535 (2001).
3. F. B. Johnson, D. A. Sinclair, L. Guarente, *Cell* **96**, 291 (1999).
4. T. B. Harris et al., *Am. J. Med.* **106**, 506 (1999).
5. D. A. Grimes, K. F. Schulz, *Lancet* **359**, 881 (2002).
6. W. Koenig, *Clin. Chem.* **47**, 9 (2001).
7. F. Van Lente, *Clin. Chim. Acta* **293**, 31 (2000).
8. R. Munford, *N. Engl. J. Med.* **344**, 1959 (2001).
9. K. J. Krause, *J. Insur. Med.* **33**, 4 (2001).
10. S. S. Levinson, R. J. Elin, *Arch. Intern. Med.* **162**, 389 (2002).
11. B. Campbell, T. Badrick, R. Flatman, D. Kanowski, *Ann. Clin. Biochem.* **39**, 85 (2002).
12. I. Kushner, A. R. Sehgal, *Arch. Intern. Med.* **162**, 867 (2002).
13. U.S. Preventive Services Task Force, *Guide to Clinical Preventive Services* (U.S. Department of Health and Human Services, Washington, DC, ed. 2, 1996) (see www.odphp.osophs.dhhs.gov/pubs/guidecps/).
14. G. L. Horowitz, B. A. Beckwith, *N. Engl. J. Med.* **343**, 512 (2000).
15. E. M. Macy, T. E. Hayes, R. P. Tracy, *Clin. Chem.* **43**, 52 (1997).
16. P. A. Sakkinen et al., *Am. J. Epidemiol.* **149**, 261 (1999).
17. C. Kluff, D. E. De Maat, *Ital. Heart J.* **2**, 172 (2001).

Atherosclerosis and Inflammation

IS ATHEROSCLEROSIS AN INFLAMMATORY disease that can occur even in the presence of "low" or "healthy" plasma concentrations of cholesterol, as Gary Taubes' article "Does inflammation cut to the heart of the matter?" (News Focus, 12 April, p. 242) implies? The answer lies in what those terms actually mean. We have argued that labeling a pathophysiologic process "inflammatory" can be misleading, because inflammation always has an underlying cause (1). For example, even though the lung is full of inflammatory cells in Pneumococcal pneumonia, the disease is considered infectious—the root cause—but with an important, secondary inflammatory reaction. Regarding atherosclerosis, a large body of experimental evidence supports the "response to retention" hypothesis of early atherogenesis: Retained or trapped low-density lipoprotein (LDL) particles within the vessel wall become enzymatically and oxidatively modified, thereby provoking, among

ADVERTISER DIRECTORY



The following organizations have placed ads in the Special Advertising Section

LABORATORY TECHNOLOGY TRENDS

Drug Discovery: 3

FROM DATA TO INFORMATION TO KNOWLEDGE


ADVERTISER	Page
Affymetrix, Inc.	639
American Type Culture Collection (ATCC)	652
Arcturus, Inc.	636
BD Biosciences	
PharMingen	641
Jouan, Inc.	645
MDL Information Systems	649
Rosetta Biosoftware	643
Tripes, Inc.	651
Upstate USA, Inc.	638
Varian, Inc.	647

Turn To Page 636

Science
WWW.SCIENCEONLINE.ORG

"Dendritic cell transfection at 40% efficiency? In my lab? Next week? Really?"

Really.



Results from independent laboratories using Nucleofector™ technology show an average transfection efficiency of 40% for human immature dendritic cells generated from monocytes (day 5-6), 24 hours post nucleofection. Graph courtesy of Dr. Sallusto and Prof. Lanzavecchia, Institute for Research in Biomedicine, Bellinzona, Switzerland and Dr. Esen, Dr. Thiel and Prof. Radbruch, Deutsches Rheuma-Forschungszentrum, Berlin, Germany.

The Nucleofector™ technology from amaxa

www.amaxa.com
+49 (0)221 99199-400

*Nucleofector™ is a trademark of amaxa

amaxa
gene transfer begins here

other things, an influx of inflammatory cells that accelerate LDL retention, early lesion development, and ultimately the progression to life-threatening plaques [reviewed in (2–6)]. In an important, recent validation of this hypothesis, LDL that was genetically engineered to be poorly retained was found to be nearly incapable of producing early atherosclerotic lesions in vivo (7).

This brings us to the question of what is a “low” or “healthy” plasma cholesterol level. Human atherosclerosis is vanishingly rare when LDL concentrations are below 80 mg/dl, regardless of other risk factors (2), and no widely accepted animal models of atherosclerosis exist that arise from either genetic derangements of immunity or distal sites of chronic inflammation in the absence of plasma lipoprotein abnormalities. Although the cholesterol levels referred to in Taubes’ article may seem low or healthy compared with the very high average values in Westerners, they are still above 80 and therefore merit serious concern.

Therapies directed at both lipoprotein retention and the responses—including inflammation—to retained material will have the greatest chance for continued

successes against atherosclerosis. We must not neglect either the primary or secondary processes in this deadly disease.

KEVIN JON WILLIAMS¹ AND IRA TABAS²

¹Division of Endocrinology, Diabetes and Metabolic Diseases, Thomas Jefferson University, 1020 Locust Street, Philadelphia, PA 19107, USA. E-mail: K_Williams@Lac.jci.tju.edu. ²Division of Molecular Medicine, Columbia University, 630 West 168th Street, New York, NY 10032, USA. E-mail: IAT1@columbia.edu

References

1. K. J. Williams, I. Tabas, *N. Engl. J. Med.* **340**, 1928 (1999).
2. ———, *Arterioscler. Thromb. Vasc. Biol.* **15**, 551 (1995).
3. E. Hurt-Camejo, U. Olsson, O. Wiklund, G. Bondjers, G. Camejo, *Arterioscler. Thromb. Vasc. Biol.* **17**, 1011 (1997).
4. K. J. Williams, I. Tabas, *Curr. Opin. Lipidol.* **9**, 471 (1998).
5. A. Chait, T. N. Wight, *Curr. Opin. Lipidol.* **11**, 457 (2000).
6. K. J. Williams, *Curr. Opin. Lipidol.* **12**, 477 (2001).
7. K. Skälén et al., *Nature* **417**, 750 (2002).

CORRECTIONS AND CLARIFICATIONS

PERSPECTIVES: “Flood basalts—bigger and badder,” by P. R. Renne (7 Jun., p. 1812). In describing the flood volcanism occurring during the last several hundred million years, the wrong units were used to describe the implied magma production rate. It should have read “on the order of 1 km³/year.”

NEWS FOCUS: “How devastating would a smallpox attack really be?” (31 May, p. 1592). A sidebar to the story about smallpox models incorrectly stated that about 1250 in every million people vaccinated against smallpox in the past suffered from serious side effects. That number, taken from a 2001 report by the Advisory Committee on Immunization Practices (ACIP), also included mild side effects and adverse reactions. For adverse reactions the ACIP classified as “moderate to severe,” the number is only 293.9 per million persons vaccinated. These include generalized vaccine (241.5 per million), eczema vaccinatum (38.5), progressive vaccinia (1.5), and postvaccinal encephalitis (12.3).

Letters to the Editor

Letters (~300 words) discuss material published in *Science* in the previous 6 months or issues of general interest. They can be submitted by e-mail (science_letters@aaaas.org), the Web (www.letter2science.org), or regular mail (1200 New York Ave., NW, Washington, DC 20005, USA). Letters are not acknowledged upon receipt, nor are authors generally consulted before publication. Whether published in full or in part, letters are subject to editing for clarity and space.


Do you need DNA, tissue or serum samples?

Bridging the gap between phenotype and genotype.

As genomic research focuses increasingly on the origins, treatment and prevention of diseases, researchers face a critical bottleneck: the ability to validate markers, using adequate numbers of consented samples with well-characterized clinical phenotypes. **GCI Access™** breaks that bottleneck.

With **GCI Access™**, researchers can now access well-characterized clinical data sets linked to DNA and snap-frozen tissue from disease patients collected from populations around the world. **GCI Access™** offers the disease cases and matched controls required to detect statistically powerful associations between genetic and phenotypic data. Each case includes extensive donor medical and family history captured through case report forms.

For more information on how we can work together, please contact our business development office at 1.877.GENOMIX.



GenomicsCollaborative

www.genomicsinc.com